Drugs / Brepocitinib
Brepocitinib
English name brepocitinib
also known as
PF-06700841 · BREPOCITINIB TOSYLATE · compound 23 · PF-06700841 TOSYLATE · PF-06700841-15
Small molecule targets JAK1, TYK2 via inhibition
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT04580797 | Oct 2020 → Jan 2021 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04267250 | Aug → Nov 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04260464 | Jul 2020 → May 2022 | impaired renal function disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04090047 | Sep → Dec 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03916250 | Mar → Apr 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03765554 | Jan → Apr 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03770039 | Dec 2018 → Feb 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03656952 | Sep 2018 → Feb 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03236493 | Aug → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02310750 | Nov 2014 → Jan 2016 | psoriasis | Pfizer | Completed | No outcome recorded |
| Phase 214 trials · 9 met primary · 2 missed | ||||||
| Phase 2 | NCT06978725 | Apr 2025 → Dec 2026 expected | skin sarcoidosis | Priovant Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06433999 | Aug 2024 → Feb 2025 | adult dermatomyositis | Priovant Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05523765 | Nov 2022 → Jul 2024 | intermediate uveitis, panuveitis, posterior uveitis | Priovant Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05076006 | May 2021 → Sep 2023 | alopecia | Emma Guttman | Completed | Met primary |
| Phase 2 | NCT04092452 | Dec 2019 → Jan 2022 | hidradenitis suppurativa | Pfizer | Completed | Met primary |
| Phase 2 | NCT03963401 | Jun 2019 → Apr 2020 | psoriatic arthritis | Pfizer | Completed | Met primary |
| Phase 2 | NCT03903822 | May 2019 → May 2020 | atopic eczema | Pfizer | Completed | Met primary |
| Phase 2 | NCT03845517 | Apr 2019 → Oct 2023 | systemic lupus erythematosus | Pfizer | Completed | Missed primary |
| Phase 2 | NCT03850483 | Apr 2019 → Apr 2021 | psoriasis | Pfizer | Completed | Missed primary |
| Phase 2 | NCT03715829 | Nov 2018 → Feb 2021 | vitiligo | Pfizer | Completed | Met primary |
| Phase 2 | NCT03395184 | Feb 2018 → Oct 2023 | Crohn disease | Pfizer | Completed | Met primary |
| Phase 2 | NCT02958865 | Feb 2017 → May 2021 | ulcerative colitis | Pfizer | Completed | Met primary |
| Phase 2 | NCT02974868 | Dec 2016 → May 2019 | alopecia areata | Pfizer | Completed | Met primary |
| Phase 2 | NCT02969018 | Dec 2016 → Mar 2018 | psoriasis | Pfizer | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07532603 | Mar 2026 → Dec 2028 expected | lichen planopilaris | Priovant Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06431373 | Sep 2024 → Sep 2026 overdue | intermediate uveitis, posterior uveitis | Priovant Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05437263 | Oct 2022 → Jul 2025 | dermatomyositis | Priovant Therapeutics, Inc. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-14 | Pfizer | Results Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress pfizer.com ↗
The findings were presented during a Late-Breaking News session at the 27th European Academy of Dermatology and Venereology (EADV) Congress in Paris, France. |
All press releases naming this drug 2 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brepocitinib | “The efficacy and safety of ritlecitinib (oral JAK3/TEC family kinase inhibitor) and brepocitinib (oral TYK2/JAK1 inhibitor) as induction therapy were assessed in patients with...” PMID 36623678 ↗ Jan 20237“brepocitinib, an inhibitor of tyrosine kinase 2 (TYK2)/JAK1 in the treatment of AA” PMID 34863853 ↗ Dec 2021 |
| Known as | BREPOCITINIB TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297477 ↗ |
| Known as | compound 23 | “the discovery of PF-06700841 (compound 23), which is in Phase II clinical development” PMID 30113844 ↗ Aug 2018 |
| Known as | PF-06700841 | “4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks” NCT03715829 ↗ |
| Known as | PF-06700841 TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297477 ↗ |
| Known as | PF-06700841-15 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297477 ↗ |
| Action | Inhibit | “The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling” PMID 31972249 ↗ Jan 2020 |
| Modality | Small molecule | “a conformationally constrained piperazinyl-pyrimidine Type 1 ATP site inhibitor” PMID 30113844 ↗ Aug 2018 |
| Route | Oral | “Delivered orally for 8 weeks.” NCT02958865 ↗ |
| Target | TYK2 | “The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling” PMID 31972249 ↗ Jan 2020 |